Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK del exon2 ALK del exon3 ALK amp |
Therapy | Ceritinib + Ribociclib |
Indication/Tumor Type | neuroblastoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK del exon2 ALK del exon3 ALK amp | neuroblastoma | sensitive | Ceritinib + Ribociclib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Zykadia (ceritinib) and Kisqali (ribociclib) inhibited proliferation in a neuroblastoma cell line harboring a deletion of ALK exons 2 and 3 and ALK amplification in culture (PMID: 27986745). | 27986745 |
PubMed Id | Reference Title | Details |
---|---|---|
(27986745) | Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. | Full reference... |